Alkermes Q3 Net Income Dips Amid Rising Product Sales, R&D Spend

Ticker: ALKS · Form: 10-Q · Filed: 2025-10-28T00:00:00.000Z

Sentiment: mixed

Topics: Biopharmaceuticals, Neuroscience, Q3 Earnings, R&D Spending, Product Sales Growth, Royalty Revenue Decline, Net Income Decrease

Related Tickers: ALKS

TL;DR

**ALKS's product sales are up, but declining royalties and higher R&D are squeezing net income, making it a 'wait and see' for sustained profitability.**

AI Summary

Alkermes plc reported a mixed financial performance for the three and nine months ended September 30, 2025. Total revenues for the three months increased to $394.185 million from $378.143 million in the prior year, driven by a significant rise in product sales, net, to $317.423 million from $272.999 million. However, manufacturing and royalty revenues decreased to $76.762 million from $105.144 million. For the nine months, total revenues slightly decreased to $1.091 billion from $1.128 billion, primarily due to a drop in manufacturing and royalty revenues from $351.835 million to $222.201 million, despite product sales increasing from $775.808 million to $869.151 million. Net income for the three months ended September 30, 2025, was $82.761 million, down from $92.381 million in the same period of 2024. Similarly, net income for the nine months decreased to $192.323 million from $220.567 million. The company's cash and cash equivalents significantly increased to $616.449 million as of September 30, 2025, from $291.146 million at December 31, 2024, largely due to $350.685 million in cash flows from operating activities for the nine months ended September 30, 2025. Research and development expenses rose to $81.739 million for the three months and $230.926 million for the nine months, up from $59.892 million and $187.152 million respectively, indicating increased investment in its neuroscience pipeline.

Why It Matters

Alkermes' mixed results, with strong product sales growth but declining royalty revenues and net income, signal a strategic shift towards proprietary products and away from licensed assets. This could impact investors by reducing reliance on third-party agreements but also introduces higher R&D risks. For employees, increased R&D spending suggests job stability and potential growth in development teams. Customers may benefit from new neuroscience treatments if pipeline investments yield successful products. In the broader market, Alkermes' performance reflects the challenges and opportunities in the biopharmaceutical sector, particularly the competitive landscape for neuroscience drugs and the pressure to innovate.

Risk Assessment

Risk Level: medium — The company's net income decreased by 10.4% for the three months ended September 30, 2025, to $82.761 million from $92.381 million in 2024, and by 12.9% for the nine months to $192.323 million from $220.567 million. This decline, coupled with a significant increase in R&D expenses by 36.5% for the three months and 23.4% for the nine months, indicates higher operational costs and potential pressure on future profitability, despite strong product sales growth.

Analyst Insight

Investors should closely monitor Alkermes' R&D pipeline progress and the commercial performance of its proprietary products like ARISTADA and LYBALVI. The significant increase in cash and cash equivalents to $616.449 million provides a buffer, but sustained net income declines could signal efficiency issues or competitive pressures. Consider holding, but be prepared to re-evaluate if R&D investments don't translate into future revenue growth.

Financial Highlights

debt To Equity
0.34
revenue
$1.091B
operating Margin
N/A
total Assets
$2.330B
total Debt
N/A
net Income
$192.323M
eps
$0.49
gross Margin
N/A
cash Position
$616.449M
revenue Growth
-3.3%

Revenue Breakdown

SegmentRevenueGrowth
Product Sales, Net$317.423M+16.3%
Product Sales, Net$869.151M+12.0%
Manufacturing and Royalty Revenues$76.762M-27.0%
Manufacturing and Royalty Revenues$222.201M-36.8%
Total Revenues$394.185M+4.2%
Total Revenues$1.091B-3.3%

Key Numbers

Key Players & Entities

FAQ

What were Alkermes plc's total revenues for the three months ended September 30, 2025?

Alkermes plc reported total revenues of $394.185 million for the three months ended September 30, 2025, an increase from $378.143 million in the same period of 2024.

How did Alkermes' net income change in Q3 2025 compared to the previous year?

Net income for Alkermes plc decreased to $82.761 million for the three months ended September 30, 2025, down from $92.381 million in the prior year's third quarter.

What was the trend in Alkermes' product sales for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Alkermes' product sales, net, increased to $869.151 million, up from $775.808 million in the corresponding period of 2024.

Did Alkermes increase its research and development spending in 2025?

Yes, Alkermes' research and development expenses increased to $230.926 million for the nine months ended September 30, 2025, compared to $187.152 million for the same period in 2024.

What is Alkermes' cash position as of September 30, 2025?

As of September 30, 2025, Alkermes plc reported cash and cash equivalents of $616.449 million, a significant increase from $291.146 million at December 31, 2024.

How many ordinary shares of Alkermes plc were outstanding as of October 24, 2025?

As of October 24, 2025, the number of Alkermes plc's ordinary shares, $0.01 par value, outstanding was 165,117,509 shares.

What factors contributed to the decrease in Alkermes' manufacturing and royalty revenues?

Manufacturing and royalty revenues for Alkermes plc decreased to $76.762 million for the three months ended September 30, 2025, from $105.144 million in the prior year, and to $222.201 million for the nine months from $351.835 million, indicating a decline in revenue from these sources.

What is Alkermes' strategic focus based on its financial report?

Alkermes plc's financial report indicates a strategic focus on developing innovative medicines in neuroscience, evidenced by increased R&D spending and growth in proprietary product sales, while manufacturing and royalty revenues have declined.

What are the primary risks Alkermes plc faces according to its 10-Q filing?

The 10-Q filing highlights risks related to financial performance expectations, product development and regulatory timelines, competitive and payer landscapes, currency exchange rate fluctuations, and intellectual property proceedings, as detailed in 'Part II, Item 1A—Risk Factors'.

How does Alkermes' diluted earnings per share compare year-over-year for Q3 2025?

Alkermes' diluted earnings per ordinary share from continuing operations decreased to $0.49 for the three months ended September 30, 2025, from $0.56 in the same period of 2024.

Risk Factors

Industry Context

Alkermes operates in the highly competitive biopharmaceutical industry, focusing on central nervous system (CNS) diseases. The industry is characterized by significant R&D investment, lengthy drug development cycles, and stringent regulatory oversight. Key trends include the increasing demand for treatments for neurological and psychiatric disorders, advancements in drug delivery technologies, and the ongoing pressure to demonstrate clinical efficacy and safety to gain market access and reimbursement.

Regulatory Implications

Alkermes faces significant regulatory risks, primarily from the FDA and similar international bodies. The approval process for new drugs is rigorous and can be lengthy, with potential for delays or rejections. Post-market surveillance and compliance with manufacturing standards are also critical. Any adverse regulatory actions or changes in regulatory policy could materially impact the company's product portfolio and financial performance.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Product sales, net
Revenue generated from the sale of the company's pharmaceutical products after deducting discounts, returns, and allowances. (Key driver of Alkermes' top-line revenue, showing a strong increase in Q3 2025.)
Manufacturing and royalty revenues
Revenue earned from manufacturing products for other companies or from royalties on sales of products licensed to others. (A significant revenue stream for Alkermes that has seen a notable decline in the reported periods.)
Research and development expenses
Costs incurred in the process of discovering, developing, and testing new pharmaceutical products. (Indicates Alkermes' investment in future growth and pipeline expansion, which has increased.)
Cash and cash equivalents
Highly liquid investments with maturities of three months or less at the time of purchase, including cash on hand and bank deposits. (Represents the company's short-term liquidity, which has significantly increased.)
Accumulated deficit
The cumulative net losses of a company since its inception, offset by any net profits. (Shows the company's historical profitability, which has improved as the deficit has decreased from $(976.458M) to $(784.135M).)
Treasury shares
Shares of the company's own stock that have been repurchased from the open market. (Represents shares held by the company, impacting the number of outstanding shares and potentially share buyback programs.)
Right-of-use assets
Assets recognized under lease accounting standards, representing the right to use an underlying asset for the lease term. (Reflects the company's leased assets, such as office or manufacturing space.)
Contract assets
Assets arising from contracts with customers that are conditional on something other than the passage of time, such as performance obligations. (Represents amounts due from customers for work performed but not yet billed or recognized as revenue.)

Year-Over-Year Comparison

Compared to the prior year, Alkermes plc. has seen a mixed financial performance. Total revenues for the nine months ended September 30, 2025, decreased by 3.3% to $1.091 billion, primarily due to a significant drop in manufacturing and royalty revenues. However, product sales, net, showed robust growth, increasing by 12.0% year-to-date. Net income has declined by 12.9% year-over-year for the nine-month period. The company has substantially strengthened its balance sheet, with cash and cash equivalents more than doubling to $616.449 million. Research and development expenses have also risen by 23.4%, indicating increased investment in future growth.

Filing Stats: 4,322 words · 17 min read · ~14 pages · Grade level 20 · Accepted 2025-10-28 09:20:51

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (unaudited): Condensed Consolidated Balance Sheets — September 30, 2025 and December 31, 2024 5 Condensed Consolidated Statements of Income and Comprehensive Income — For the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows — For the Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Shareholders' Equity — For the Three and Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 36

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 37 Item 1A.

Risk Factors

Risk Factors 37 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 39 Item 5. Other Information 39 Item 6. Exhibits 40

Signatures

Signatures 41 2 Cautionary Note Concerning Forward-Looking Statements This document contains and incorporates by reference "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In some cases, these statements can be identified by the use of forward-looking terminology such as "may," "will," "could," "should," "would," "expect," "anticipate," "continue," "believe," "plan," "estimate," "intend" or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward-looking information. Forward-looking statements in this Quarterly Report on Form 10-Q (this "Form 10-Q") may include, without limitation, statements regarding: our expectations regarding our financial performance, including revenues, expenses, liquidity, capital expenditures, income taxes and profitability; our expectations regarding our products, including expectations related to product development, regulatory filings, approvals and timelines; therapeutic and commercial value, scope and potential; and the costs and expenses related to such activities and expectations; our expectations regarding the timing, design and results of clinical trials of our products; our expectations regarding the competitive, payer, legislative, regulatory and policy landscape, and changes therein, related to our products, including competition from generic forms of our products or competitive products and development programs; barriers to access or coverage of our products and potential changes in reimbursement of our products; and legislation, regulations, executive orders, guidance or other measures that may impact pricing and reimbursement of, and access to, our products; our expectations regarding the financial impac

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

Condensed Consolid ated Financial Statements

Item 1. Condensed Consolid ated Financial Statements: ALKERMES PLC AND SUBSIDIARIES CONDENSED CONSOLIDA TED BALANCE SHEETS (unaudited) September 30, 2025 December 31, 2024 (In thousands, except share and per share amounts) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 616,449 $ 291,146 Investments—short-term 494,665 460,522 Receivables, net 354,394 384,528 Inventory 190,997 182,887 Prepaid expenses and other current assets 84,442 91,282 Contract assets 717 4,990 Total current assets 1,741,664 1,415,355 PROPERTY, PLANT AND EQUIPMENT, NET 246,982 227,564 INVESTMENTS—LONG-TERM 27,869 73,148 RIGHT-OF-USE ASSETS 79,128 84,245 INTANGIBLE ASSETS, NET AND GOODWILL 83,861 83,917 DEFERRED TAX ASSETS 130,344 154,835 OTHER ASSETS 19,664 16,503 TOTAL ASSETS $ 2,329,512 $ 2,055,567 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses $ 214,985 $ 185,332 Accrued sales discounts, allowances and reserves 252,743 272,452 Operating lease liabilities—short-term 6,632 6,166 Contract liabilities—short-term — 1,249 Total current liabilities 474,360 465,199 OPERATING LEASE LIABILITIES—LONG-TERM 64,966 69,372 OTHER LONG-TERM LIABILITIES 56,754 56,019 Total liabilities 596,080 590,590 COMMITMENTS AND CONTINGENT LIABILITIES (Note 16) SHAREHOLDERS' EQUITY: Preferred shares, par value, $ 0.01 per share; 50,000,000 shares authorized; and zero issued and outstanding at September 30, 2025 and December 31, 2024 — — Ordinary shares, par value, $ 0.01 per share; 450,000,000 shares authorized; 180,499,470 and 176,670,785 shares issued; and 165,103,891 and 162,176,994 shares outstanding at September 30, 2025 and December 31, 2024, respectively 1,805 1,767 Treasury shares, at cost ( 15,395,579 and 14,493,791 shares at September 30, 2025 and December 31, 2024, respectively) (

View on Read The Filing